Supplementary Information(HNS-COVID-PK Trial)

TABLE OF CONTENT:

Contents	Page
	Number
Team of investigators	3
Trial executive committee:	7
Trial steering committee	9
Additional details on participants	10
Figure S1: Enrolment criteria	11
Figure S2: SSC-2 (Shaikh Zayed SARS-CoV-2) SCORE	12
Additional details on randomization	13
Additional details on interventions	13
Additional details on outcomes	14
Figure S3: Participant timeline	18
Additional details on statistical analyses	21
Table S1. Baseline table	26
Table S2. Distribution of severity of cough over days	31
Table S3. Distribution of Severity of Symptoms over days	32
Table S4. Distribution of fever over days	33
Table S5. Distribution of Myalgia over days	34
Table S6. Distribution of Shortness of Breath over days	35
Table S7. Variation of oxygen saturation over days	36
Table S8. Distribution of How sick do you feel over days	37
Table S9 Variation of emotional status over days	38
Table S10 Variation of clinical status grading over days	40

TEAM OF INVESTIGATORS

Study Chair:

Muhammad Ashraf, PhD (University of Minnesota)

Institutional Affiliation: University of Veterinary & Animal Sciences, Lahore, Pakistan

Study Director:

Shoaib Ashraf, PhD (McGill University)

Institutional Affiliation: Massachusetts General Hospital, Harvard University, Boston, USA

Study Principal Investigators:

1. Moneeb Ashraf, MBBS, M.Phil. (Pharmacology).

Institutional Affiliation: King Edward Medical University, Mayo Hospital, Lahore, Pakistan

2. Sohaib Ashraf, MBBS

Institutional Affiliation: Shaikh Zayed Post-Graduate Medical Complex, Lahore, Pakistan

Study Co-Investigators:

1. Ali Ahmad, PhD (Cornell University)

Institutional Affiliation: Centre Hospitalier Universitaire (CHU) Sainte Justin/University of Montreal, Montreal, Canada.

2. Muhammad Ahmad Imran, MBBS

Institutional Affiliation: Federal Post-Graduate Medical Institute, Lahore, Pakistan

Principal Investigator (SZH):

1. Mateen Izhar, MBBS, PhD, FRCPath

Institutional Affiliation: Shaikh Zayed Medical Complex, Lahore, Pakistan

2. Ayesha Humayun, MBBS, PhD

Institutional Affiliation: Shaikh Zayed Medical Complex, Lahore, Pakistan

Co-Investigators (SZH):

1. Qazi Abdul Saboor, MBBS, FCPS (Cardiology)

Institutional Affiliation: Shaikh Zayed Medical Complex, Lahore, Pakistan

2. Talha Mahmood, MBBS, MD, FCPS (Pulmonology)

Institutional Affiliation: Shaikh Zayed Medical Complex, Lahore, Pakistan

3. Uzma Nasim Siddiqui, MBBS, FCPS (Medicine)

Institutional Affiliation: Shaikh Zayed Medical Complex, Lahore, Pakistan

4. Abubakar Hilal, MBBS, FCPS (Cardiology)

Institutional Affiliation: Shaikh Zayed Medical Complex, Lahore, Pakistan

Site Investigators (SZH):

- 1. Ammara Ahmad, MBBS
- 2. Usama Farooq, MBBS
- 3. Saif-ul-wahab, MBBS
- 4. Ansar Maqbool, MBBS
- 5. Zeeshan Shaukat, MD
- 6. Umair Hafeez, MBBS
- 7. Tayyab Mughal, MBBS
- 8. Ayesha Khaqan, MBBS
- 9. Qurrat-ul-ain Iqbal, MBBS
- 10. Hassan Riaz, MBBS
- 11. Kanwal Hayat, BSc (Nursing)
- 12. Ghazala BSc(Nursing)
- 13. Mehak Gul, BSc (Nursing)

Principal Investigator (SIMS):

1. Mahmood Ayyaz, MBBS, FCPS, FRCSEd, FICS, FACS

Institutional Affiliation: Services Institute of Medical Sciences, Lahore, Pakistan.

Co-Investigators (SIMS):

1. Nighat Majeed, MBBS, FCPS(Medicine)

Institutional Affiliation: Services Hospital, Lahore, Pakistan

2. Larab Kalsoom, MBBS

Institutional Affiliation: Services Hospital, Lahore, Pakistan

Site Investigators (SIMS):

- 1. Iqra Farooq, MBBS
- 2. Abeer Bin Awais, MBBS
- 3. Hassan Mujtaba Cheema, MBBS
- 4. Abdur Rehman Virk, MBBS
- 5. Mehak Gul, MBBS
- **6.** Ammara Ahmad, MBBS
- 7. Rashida Sharif, BSc (Nursing)

Investigators (Ali Clinic):

- 1. Zaighum Habib, MBBS, MS
- 2. Zain-ul-Abdin, MBBS
- 3. Shahroz Arshad, MBBS
- 4. Misbah Kousar, (BSc Nursing)

Investigators (Doctors Lounge):

- 1. Sundas Rafique, MBBS
- 2. Suneela Ahmad, MBBS
- 3. Sarmad Shahab, MBBS
- 4. Sumaira Hamid, BSc (Nursing)

LEAD BIOSTATISTICIANS:

Zheng Hui, PhD

Institutional Affiliation: Massachusetts General Hospital, Boston, MA, USA

Harvard Medical School, Boston, MA, USA

Muhammad Azam, PhD

Institutional Affiliation: University of Veterinary & Animal Sciences, Lahore, Pakistan

Sohail Ahmad, PhD

Institutional Affiliation: University of Veterinary & Animal Sciences, Lahore, Pakistan

Muhammad Kiwan Akram, M.Phil.

Institutional Affiliation: University of Veterinary & Animal Sciences, Lahore, Pakistan

RESEARCH PHARMACISTS & DRUG SAFETY PANELISTS:

1. Syed Muhammad Muneeb, PharmD, PhD

Institutional Affiliation: Institute of Pharmaceutical Sciences, University of Veterinary & Animal Sciences, Lahore, Pakistan

2. Muhammad Faisal Nadeem, PharmD, PhD

Institutional Affiliation: Institute of Pharmaceutical Sciences, University of Veterinary & Animal Sciences, Lahore, Pakistan

TRIAL EXECTIVE COMMITTEE:

• Muhammad Ashraf, DVM, PhD (University of Minnesota)

Institutional Affiliation: University of Veterinary & Animal Sciences, Lahore, Pakistan

• Shoaib Ashraf, BSc (Medical Lab Technology) DVM, PhD (McGill University)

Institutional Affiliation: Riphah College of Veterinary Sciences, Riphah University, Lahore, Pakistan.

• Sidra Ashraf, BSc (Medical Lab Technology), M.Phil.

Institutional Affiliation: University of Veterinary & Animal Sciences, Lahore, Pakistan

• Moneeb Ashraf, MBBS, M.Phil. (Pharmacology).

Institutional Affiliation: Kingeward Medical University, Mayo Hospital, Lahore Pakistan

• Sohaib Ashraf, MBBS

Institutional Affiliation: Shaikh Zayed Medical Complex, Lahore, Pakistan

• Ali Ahmad, DVM, PhD

Institutional Affiliation: University of Montreal, Sainte Justin Hospital, Montreal, Canada.

• Mateen Izhar, MBBS, PhD, FRCPath

Institutional Affiliation: Shaikh Zayed Medical Complex, Lahore, Pakistan

Mahmood Ayyaz MBBS, FCPS, FRCS, FACS

Institutional Affiliation: Services Institute of Medical Sciences, Lahore, Pakistan.

• Ayesha Humayun, MBBS, FCPS, PhD

Institutional Affiliation: Shaikh Khalifa bin Zayed Al-Nahyan Medical & Dental College, Lahore, Pakistan

• Talha Mahmood, MBBS, FCPS, MD (Pulmonology)

Institutional Affiliation: Shaikh Zayed Medical Complex, Lahore, Pakistan

• Qazi Abdul Saboor, MBBS, FCPS (Cardiology)

Institutional Affiliation: Shaikh Zayed Medical Complex, Lahore, Pakistan

• Nighat Masood, MBBS, FCPS (Medicine)

Institutional Affiliation: Services Institute of Medical Sciences, Lahore, Pakistan.

• Uzma Nasim Siddique, MBBS, FCPS (Medicine)

Institutional Affiliation: Shaikh Zayed Medical Complex, Lahore, Pakistan

• Sundas Rafique, MBBS

Institutional Affiliation: Kingedward Medical Institute, Mayo Hospital, Lahore, Pakistan

• Zain-ul-abdin, MBBS

Institutional Affiliation: Shaikh Zayed Hospital, Lahore, Pakistan

• Muhammad Ahmad Imran, MBBS

Institutional Affiliation: Federal Post-Graduate Medical Institute, Lahore, Pakistan.

• Larab Kalsoom, MBBS

Institutional Affiliation: Services Hospital, Lahore, Pakistan

• Muhammad Kiwan Akram, M.Phil. (Nutrition)

Institutional Affiliation: UVAS, Lahore, Pakistan

• Kanwal Hayat, BSc (Nursing)

Institutional Affiliation: Shaikh Zayed Hospital, Lahore, Pakistan

TRIAL STEERING COMMITTEE

• Muhammad Imran, PhD

Institutional Affiliation: Massachusetts Institute of Technology, Boston, USA

• Yasir Zahoor, PhD

Institutional Affiliation: Boston Children Hospital, Harvard Medical School, USA

• Umer Naveed, PhD

Institutional Affiliation: Royal (Dick) School of Veterinary Studies and Roslin

Institute, Scotland, UK

• Fazli Mabood, PhD

Institutional Affiliation: CHU Sainte-Justine Hospital, University of Montreal,

Canada

• Muhammad Bilal, M.Phil.

Institutional Affiliation: McGill University, Sainte-Anne-de-Bellevue, Quebec,

Canada

• Syed Kazim Ali, LLB

Institutional Affiliation: Lahore High Court Bar, Pakistan

United Nations for Human Rights

• Asad-ullah, Pharm.D, M.Phil.

Institutional Affiliation: Drug Regulation Authority Pakistan (DRAP)

• Zaka-ur-Rehman, PhD

Institutional Affiliation: Ministry of Health Punjab, Pakistan.

Supplemental Methods

Additional Details on Participants

All COVID-19 patients presented in study settings of Pakistan during the study period were enrolled.

Inclusion Criteria:

- All suspected patients with an SSC-2 score (Figure 2) fulfilling the enrolment criteria (Figure 1)
- Positive RT-PCR (Real Time Polymerase Chain Reaction)
- Patients who presented to seek medical care within 96 hours of ailment/randomization with positive RT-PCR and normal baseline laboratory parameters
- Varying degree of COVID-19 disease severity
- Both genders with age 18 years and above

Exclusion Criteria:

- Presence of co-morbidities like liver disease, immuno-compromised patient or any other chronic ailment (other than Diabetes and Hypertension)
- Females who are pregnant and breast feeding
- Uncontrolled Diabetes Mellitus and Hypertension
- If a patient is allergic to either honey or *Nigella sativa*.
- Refusal or withdrawal from informed consent.
- patient on ventilator support or PaO2/FIO2 of less than 100
- Hemodynamic instability
- Patients with positive SARS-CoV-2 screening during elective lists for any procedure were also excluded.

All suspected patients were assessed on SSC-2 score. If a score is less than 5, the patient was excluded from the study. If the score was ≥5, SARS-CoV-2 RT-PCR performed, if first RT-PCR negative, patient was excluded but if PCR was positive, patient included. (This decision is made on first RT-PCR).

Enrolment Criteria:




Figure S1: Enrollment criteria for suspected COVID-19 patients.

SSC-2 (Shaikh Zayed SARS-CoV-2) SCORE

High grade Fever (without any other evident source of infection)	5
Low grade Fever (without any other evident source of infection)	3
Fever (with evident source of infection)	2
Fatigue/Myalgia	2
Dry Cough	2
Dyspnea	3
Any Atypical Symptom*	1
ARDS`	5
Any other diagnosis unlikely	2

Score of less than 5: Low probability

Score of between 5 &10: Moderate probability (need PCR to label as Corona infected

Patient)

Score of more than 10: High probability

Figure S2: A score based on prevalence of symptoms reported to diagnose/ suspect patients with corona as per reported in multiple studies in COVID-19 patients.

^{*(}Headache, Anorexia, Sputum production, Pharyngitis, GI disturbances)

Additional Details on the Randomization

As a pilot project 15 patients in each arm was initiated for this multi-centered study in Pakistan. Later, this study was expanded considering the feasibility of the trial, for the 3 months from start of study (30/4/2020 to 29/7/2020). Stratification was done via SAS version 9.4 for initial COVID-19 status (or days from initial symptoms as a proxy), age groups, gender, additional drugs administered, base line severity of symptoms and co-morbidities was used to ensure that groups remain balanced in size for either arm after written informed consent to participate in our study. Randomization was done using a lottery method. To minimize allocation bias, we performed allocation concealment with an interactive voice/web-based response system until randomization was finished on the system through a computer or phone. The allocation sequence was computer generated that was concealed from all site investigators, allocated participants and treatment providers until the final interventional allocation.

Additional details on interventions

Both arms received standard care as per advised by treating physician and "Clinical Management Guidelines for COVID-19 by Ministry of National Health Services, Pakistan", standard care administered was comprised primarily of anti-pyretic, analgesics, antibiotics, multi-vitamins, intravenous fluids, supplemental oxygen, invasive/noninvasive ventilation, immune-modulatory agents, and inotropic support. The placebo comparator group received an empty capsule as a placebo in addition to standard care while the intervention arm received honey and Nigella sativa an add-on. Nigella sativa seeds (80 mg/kg/day) were grinded and packed in capsules which was be given to the interventional group along with 1 gm/kg/day of honey stirred in 250ml of warm water in 2 to 3 divided doses, for a maximum of 13 days or the patient completely recovered. To improve adherence to the intervention, participants were counselled about the advantages of this study. All the participants were monitored regarding compliance to their assigned treatment strategy. As this trial included admitted patients and patients enrolled via telemedicine and OPD direct observational method was followed for admitted patients and structured telephone calls for 13 days was used to make sure compliance and adherence to the interventions for telemedicine and OPD enrolled patients (in case, whenever a OPD patient missed a visit in his/her follow up 13th day period).

Additional details on outcomes:

Primary Outcomes:

- Time taken for alleviation of symptoms (Date of asymptomatic-Date of randomization)
- Time taken for viral load clearance (Date of 1st Negative PCR (done once patient was 48 hours asymptomatic after treatment) -Date of 1st Positive PCR)
- Clinical status grading at Day 6 (defined by seven-point ordinal scale as per World Health Organization R&D Blueprint Ordinal Clinical Scale).

Secondary Outcomes:

- Degree of Fever at day 4
- CRP level measured at day 6
- Severity of symptoms at day 8
- Clinical Status grading at day 10
- 30 Day Mortality

Additional Outcomes:

Median time to clinical improvement of severity of symptoms, degree of fever, severity of cough, degree of shortness of breath, degree of myalgia and emotional status.

RT-PCR: was done on enrolment day (i.e. day 0) which was repeated once patient became asymptomatic for more than 48 to 72 hours. If the PCR would still be positive, it was repeated on day 14th. RT-PCR is shown as positive or negative.

OPERATIONAL DEFINITION

Cough

1. None: No cough.

2. Mild: Occasional, transient cough

3. Moderate: Frequent cough, slightly influencing day time activities

4. Severe: Frequent cough, significantly influencing daytime activities

Fever

1. None: <99 °F

2. Mild: 99-100 °F

3. Moderate: 100-101.9 °F

4. Severe: $> 102^{\circ}F$

Myalgia

It was classified as mild, moderate and severe on subjective basis. Patients have been provided with a scale of 1-10, with 1 being the lowest and 10 being the highest value.

1. None: 0

2. Mild: 1-3

3. Moderate: 4-6

4. Severe: >6-10

Shortness of Breath

It was classified as Grade1, Grade2, Grade3, Grade4 and Grade5.

1. Grade1= Not troubled by breathlessness except on strenuous exercise

2. Grade 2= Short of breath when hurrying on the level or walking up a slight hill

3. Grade 3= Walks slower than most people on the level, stops after a mile or so, or stop after 15 minutes walking at own pace

4. Grade 4= Stops for breath after walking about 100yds or a few minutes on level ground

5. Grade 5= Too breathless to leave the house, or breathless when undressing

How Sick Do You Feel

It was classified as mild, moderate and severe on subjective basis. Patients have been provided with a scale of 1-10, with 1 being the highest and 10 being the lowest

1. None: 10

2. Mild: >6-9

3. Moderate: 4-6

4. Severe: 1-3

Time Taken for alleviation of symptoms:

Number of days taken by the patients in experimental and control groups for resolution of symptoms.

Grading of Clinical Status:

Grading of clinical status was assessed at 0, 4, 6, 8, 10, 12th day considering patient condition on that moment.

- Grade 1. Not hospitalized with resumption of normal daily life activities
- Grade 2. Not hospitalized but unable to resume normal daily life activities
- Grade 3. Hospitalized, but do not require supplemental oxygen therapy
- Grade 4. Hospitalized but require low flow supplemental oxygen therapy
- Grade 5. Hospitalized, requiring high flow supplemental oxygen
- Grade 6. Hospitalized, requiring mechanical ventilation
- Grade 7. Death

<u>Severity of respiratory symptoms</u> is classified as mild, moderate, severe and Acute Respiratory Distress Syndrome (ARDS)

- 1. None: Baseline health of patient.
- 2. Mild: "symptoms of an upper respiratory tract viral infection i.e. low-grade fever, dry cough, sore throat, nasal congestion, malaise but no radiological evidence of pneumonia"
- 3. Moderate: "Moderate disease includes patients with Hypoxia (Oxygen saturation <94% but >90%) or chest X-ray with infiltrates involving <50% of the lung fields or fever, cough, sputum production, and other respiratory tract or non-specific symptoms along with manifestation of pneumonia on imaging but no signs of severe pneumonia"
- 4. Severe: "Fever is associated with severe dyspnoea, respiratory distress, tachypnea (> 30 breaths/min), and hypoxia (SpO2 < 94% on room air)" or a PaO2 to FiO2 ratio of 300 or lower.

			STUDY PERIOD													
	Enrolment Allocation		Post-allocation								Follow-up					
TIME POINT	Day 0	Day 1	Day 2	Day 3	Day 4	Day 5	Day 6	Day 7	Day 8	Day 9	Day 10	Day 11	Day 12	Day 13	Day 14	Day 30
ENROLMENT:																
Eligibility screen Randomization	X															
Informed consent	X															
Demographics [1]	X															
Medical history and epidemiological information [2]	X															
INTERVENTIONS:																
Honey and Nigella sativa		X	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х		
Placebo		X	X	X	X	X	Х	Х	Х	X	Х	Х	Х	X		

							1								ı	1
ASSESSMENTS:																
Physical exam [3]	X															
Vital signs ^[4]	X															
CBC [5]	X															
LFTs [5]	X															
RFTs [5]	X															
Clinical evaluation	X															
12 lead ECG	X															
Chest X-ray	X															
Alleviation of symptoms	Х		•													-
RT-PCR [6]		•														-
Clinical Grading Status on 7-pointer	X				X		X		X		X		X			
scale																
Fever	X	X	X	X	X	X	X	X	X	X	X	X	X	X		
Cough	X	X	X	X	X	X	X	X	X	X	X	X	X	X		

Shortness of breath	X	X	X	X	X	X	X	X	X	X	X	X	X	X	
Myalgia	X	X	X	X	X	X	X	X	X	X	X	X	X	X	
Rate your emotional status	X	X	X	X	X	X	Х	X	Х	Х	Х	Х	Х	X	
How sick do you feel	X	X	X	X	X	X	X	X	X	X	X	X	X	X	
Oxygen saturation on room air	X	X	X	X	X	X	X	X	X	X	X	X	X	X	
Oxygen Therapy	X	X	X	X	X	X	X	X	X	X	X	X	X	X	
Adverse effects of drug administration	X	X	X	X	X	X	X	X	X	X	X	X	X	X	
Mortality			•												-

Figure S3: Schedule of enrollment, interventions, and assessments according to the Standard Protocol Items. [1] Demographics include Name (optional), Age, Gender, Contact Number (mandatory), Profession, Blood group. [2] Epidemiological information includes recent travel history and exposure to epidemic area or infected patients; medical history includes present illness and past medical history including co-morbidity and medications. [3] Physical examination includes height, weight, general outlook, head, eye, ear, nose, throat, neck and thyroid, skin, cardiovascular system, Anterior chest and lung, abdomen, neuro system, skeletal muscle system and lymphatic system. [4] Vital signs: body temperature, respiratory rate, pulse, blood pressure; record maximum temperature of the visiting day and use same measurement criteria throughout the study period. [5] Laboratory parameters be exempted by the investigators if the participants can provide qualified examination results within 48 hours prior to initiation of the study [6] Second PCR will be performed 48 to 72 hours after the patient becomes asymptomatic if it's still positive another PCR will be conducted on day 14th

Additional Details on Statistical Analyses

Biostatistician using SAS software version 9.4 analysed all trial data. Mean \pm S.D was used for quantitative data and f (%) was be used for categorical data. Frequency and percentages were measured for categorical data. Data supporting the necessary assumptions of time to event data, survival analysis/ Kaplan Meier test was applied. P-value < 0.05 was considered as significant.

Outcome	Hypothesis	Outcome measure	Method of analysis
PRIMARY OUTCOMES		,	
1. Time Taken for Alleviation of Symptoms	Earlier resolution of symptoms	Yes/No	Multivariant analysis, cox proportional hazards
2. Viral Load Clearance	Earlier RT-PCR negative	Positive/ negative	models
3. Clinical Grading Score (CGS) at Day 6	Lower CGS score on seven pointer ordinal scale at day 6	Grade from 1-7 Grade 1. Not hospitalized with resumption of normal daily life activities Grade 2. Not hospitalized but unable to resume normal daily life activities Grade 3. Hospitalized, but do not require supplemental oxygen therapy Grade 4. Hospitalized but require low flow supplemental oxygen therapy Grade 5. Hospitalized, requiring high flow supplemental oxygen Grade 6. Hospitalized, requiring mechanical ventilation Grade 7. Death	Mixed Ordinal Logistic Regression Model

SECONDARY OUTCOMES			
1. Degree of fever at day 4	Lower degree of fever at day 4	Yes/No	Mixed Ordinal Logistic Regression Model
2. CRP at Day 6	Lower CRP levels at day 6	Yes/No	Linear regression model
3. Severity of symptoms at day 8	Lower degree of severity at	Severity of symptoms is classified as mild,	Mixed Ordinal Logistic
	day 8	moderate or severe.	Regression Model
4. Clinical Grading Score (CGS) at Day 10	Lower CGS score on seven pointer ordinal scale at day 10	Grade from 1-7 Grade 1. Not hospitalized with resumption of normal daily life activities Grade 2. Not hospitalized but unable to resume normal daily life activities Grade 3. Hospitalized, but do not require supplemental oxygen therapy Grade 4. Hospitalized but require low flow supplemental oxygen therapy Grade 5. Hospitalized, requiring high flow supplemental oxygen Grade 6. Hospitalized, requiring mechanical ventilation Grade 7. Death	Mixed Ordinal Logistic Regression Mode
5. 30 Day Mortality	Lower mortality	Yes/No	Fisher's Exact test

ADDITIONAL OUTCOMES			
Median time to clinical improvement of seven	rity of symptoms		
Improvement of one category on ordinal scale	Earlier improvement in	1. None	Univariate Log-rank test
Improvement of two category on ordinal scale	severity of symptoms	2. Mild	
Achievement of normal status on ordinal		3. Moderate	
scale		4. Severe	
Median time to clinical improvement of degr	ee of fever		
Improvement of one category on ordinal scale	Earlier improvement in degree of fever	1. None: <99 °F 2. Mild: 99-100 °F	Univariate Log-rank test
Improvement of two category on ordinal scale		3. Moderate: 100-101.9 °F4. Severe: ≥ 102°F	
Achievement of normal status on ordinal			
scale			
Median time to clinical improvement of coug	h		1
Improvement of one category on ordinal scale	Earlier improvement in degree of cough	 None: No cough. Mild: Occasional, transient cough 	Univariate Log-rank test
Improvement of two category on ordinal scale		3. Moderate: Frequent cough, slightly influencing day time activities5. Severe: Frequent cough, significantly	
Achievement of normal status on ordinal scale		influencing daytime activities	

Median time to clinical improvement of shor	tness of breath		
Improvement of one category on ordinal scale	Earlier improvement in degree of shortness of breath	Grade1= Not troubled by breathlessness except on strenuous exercise Grade 2= Short of breath when hurrying on the level or walking up a slight hill	Univariate Log-rank test
Improvement of two category on ordinal scale	oreach	Grade 3= Walks slower than most people on the level, stops after a mile or so, or stop after 15 minutes walking at own pace Grade 4= Stops for breath after walking about	
Achievement of normal status on ordinal		100yds or a few minutes on level ground.	
scale		Grade 5= Too breathless to leave the house, or breathless when undressing	
Median time to clinical improvement of mya	lgia		
Improvement of one category on ordinal scale	Earlier improvement in	1. None	Univariate Log-rank test
Improvement of two category on ordinal scale	degree of myalgia	2. Mild	
Achievement of normal status on ordinal		3. Moderate	
scale		4. Severe	
Median time to clinical improvement of "how	w sick do you feel"		
Improvement of one category on ordinal scale	Earlier improvement in	1. None	Univariate Log-rank test
Improvement of two category on ordinal scale	status "How sick do you	2. Mild	
Achievement of normal status on ordinal	feel"	3. Moderate	
scale		4. Severe	

 $\textbf{Figure S4: Statistical Analysis.} \ \ \text{Two tailed P-value} < 0.05 \ \ \text{with 95\%} \ \ \text{confidence interval was considered as significant.}$

SUPPLEMENTARY TABLES

Baseline Demographics	Total	Standard	Honey-Nigella	
	(n=313)	Care Alone (n=156)	Sativa (n=157)	
Age (Year) — No. (%)		1		
≤40	156 (49.84)	80 (25.56)	76 (24.28)	
40-59	93 (29.71)	45 (14.38)	48 (15.34)	
60-79	52 (16.61)	26 (8.31)	26 (8.31)	
≥80	12 (3.83)	5 (1.6)	7 (2.24)	
Sex — No. (%)				
Male	178 (56.87)	88 (56.41)	90 (57.32)	
Female	135 (43.13)	68 (43.59)	67 (42.68)	
Profession — No. (%)				
Health care¶	71 (22.68)	38 (24.36)	33 (21.02)	
Non-Health care	242 (77.32)	118 (75.64)	124 (78.98)	
Co-Morbidities — No. (%)				
Hypertension	99 (31.63)	51 (16.29)	48 (15.34)	
Diabetes Mellitus	115 (36.74)	60 (19.17)	55 (17.57)	
Onset of symptoms before adn	mission — No. (%)			
48 hours	88 (38.1)	49 (41.53)	39 (34.51)	
72 hours	143 (61.9)	69 (58.47)	74 (65.49)	
96 hours	82 (36.44)	38 (35.51)	44 (37.29)	
Severity of Symptoms — No. ((%)			
Moderate	210 (67.09)	103 (66.03)	107 (68.15)	
Severe	103 (32.91)	53 (33.97)	50 (31.85)	

ARDS —No. (%)	57 (17.38)	28 (17.95)	29 (16.86)
Chest X-Ray — No. (%)	<u> </u>	<u>l</u>	
Normal	217 (66.16)	101 (30.79)	116 (35.37)
Pneumonic Patch	12 (3.66)	8 (2.44)	4 (1.22)
Unilateral Infiltrates	40 (12.2)	19 (5.79)	21 (6.4)
Bilateral Infiltrates	59 (17.99)	28 (8.54)	31 (9.45)
ECG — No. (%)			
Normal	230(73.48)	119(38.02)	111(35.46)
LBBB	62(19.81)	28(8.95)	34(10.86)
Other	21(6.71)	9(2.88)	12(3.83)
Clinical Status Grading at Day 0 —	No. (%)	<u>I</u>	
2- Not hospitalized with unable to resume normal activities — No. (%)	139 (44.41)	68 (43.59)	71 (45.22)
3- Hospitalized, not requiring supplemental oxygen — No. (%)	71 (22.68)	35 (22.44)	36 (22.93)
4- Hospitalized, requiring low flow supplemental oxygen — No. (%)	44 (14.06)	23 (14.74)	21 (13.38)
5- Hospitalized, requiring high flow supplemental oxygen — No. (%)	59 (18.85)	30 (19.23)	29 (18.47)
Hospital — No. (%)			
Shaikh Zayed Hospital	78 (25.66)	39 (25.83)	39 (25.49)
Services Institute of Medical Sciences	91 (29.93)	48 (31.79)	43 (28.1)
Doctors Lounge	52 (17.11)	27 (17.88)	25 (16.34)
Ali Clinic ^{III}	83 (27.3)	37 (24.5)	46 (30.07)

equency of Symptoms — No. (%)			
Fever	303 (96.81)	152 (48.56)	151 (48.24)
SOB	106 (33.87)	56 (17.89)	50 (15.97)
Cough	192 (61.34)	90 (28.75)	102 (32.59)
Myalgia	169 (53.99)	89 (28.43)	80 (25.56)
Sputum	23(7.35)	13(4.15)	10(3.19)
Anorexia	63(20.13)	31(9.9)	32(10.22)
Fatigue	47(15.02)	27(8.63)	20(6.39)
Loss of smell	76(24.28)	36(11.5)	40(12.78)
Change in taste	77(24.6)	39(12.46)	38(12.14)
atment Options — No. (%) ¥			
Panadol	297 (94.89)	147 (46.96)	150 (47.92)
Azithromycin	231 (73.8)	120 (38.34)	111 (35.46)
Montelukast	106 (33.87)	56 (17.89)	50 (15.97)
Supplemental Oxygen	105 (33.55)	55 (17.57)	50 (15.97)
Low Molecular Weight Heparin	72 (23)	38 (12.14)	34 (10.86)
Hydrocortisone	83 (26.52)	45 (14.38)	38 (12.14)
Multivitamins	147 (46.96)	73 (23.32)	74 (23.64)
Tazobactam + Piperacillin	73 (23.32)	42 (13.42)	31 (9.9)
Ivermectin	114 (36.42)	60 (19.17)	54 (17.25)
Meropenem	62 (19.81)	35 (11.18)	27 (8.63)
Ibuprofen	101(32.27)	57(18.21)	44(14.06)

Blood Group—No. (%)			
A+	92(29.39)	45(14.38)	47(15.02)
A-	7(2.24)	2(0.64)	5(1.6)
B+	96(30.67)	54(17.25)	42(13.42)
В-	19(6.07)	12(3.83)	7(2.24)
AB+	50(15.97)	24(7.67)	26(8.31)
AB-	11(3.51)	2(0.64)	9(2.88)
O+	28(8.95)	11(3.51)	17(5.43)
0-	10(3.19)	6(1.92)	4(1.28)
Vitals—No. (%)	<u> </u>	<u> </u>	
Systolic Blood Pressure, median (IQR) — mm of Hg	120(110- 140)	120(110- 140)	120(110-140)
Diastolic Blood Pressure, median (IQR) — mm of Hg	80(70-85)	80(70-85)	80(70-90)
Temperature, median (IQR) — °F	101(100- 102)	101(100- 102)	101(100-102)
≤100°F — No. (%)	89(28.43)	46(14.7)	43(13.74)
100°F-102°F — No. (%)	100(31.95)	46(14.7)	54(17.25)
≥102°F —No. (%)	124(39.62)	64(20.45)	60(19.17)
Respiratory Rate, median (IQR) — breaths per minute	19(18-25)	20.50(18-26)	18(18-24)
Heart Rate, median (IQR) — beats per minute	87(78-105)	88(78-106)	86(78-100)

Laboratory Parameters			
Hemoglobin, median (IQR) — mg/dL	13.30(12.60- 14.20)	13.30(12.60- 14.20)	13.30(12.40- 14.20)
Total Leukocyte Count, median (IQR) — mg/dL	6.40(5.60- 7.70)	6.40(5.60- 8.40)	6.30(5.50-7.40)
Neutrophils, median (IQR) — mg/dL	6.0(4.70- 6.90)	6.05(4.70- 7.10)	5.90(4.70-6.90)
Lymphocyte, median (IQR) — mg/dL	1.90(1.60- 2.30)	1.90(1.60- 2.40)	1.90(1.60-2.30)
Platelets, median (IQR) — mg/dL	229(189- 255)	229(189- 264)	223(188.0- 253.0)
ALT, median (IQR) — U/L	43(39-47)	43(38-47)	44(40.0-48.0)
AST, median (IQR) — U/L	33(29.0- 38.0)	32(29-28)	33(29.0-38.0)
Creatinine, median (IQR) — mg/dL	1(1.0-1.1)	1(0.9-1.20)	1(1.0-1.1)
≤ 1.3mg/dL — No. (%)	295(147)	148(94.87)	147(93.63)
>1.3mg/dL — No. (%)	18(10)	8(5.13)	10(6.37)
CRP, median (IQR) — mg/L	16(11-21)	17(12-21)	14(10.0-21.0)
O2 Saturation at room air, median (IQR) — (%)	96(87-96)	96(86-96)	96(87-97)

^{*}Data are presented as no. (%) unless indicated otherwise. The Intention-to-Treat Population included all the patients who had undergone randomization. Information on co-morbidities, profession, age and gender was obtained from medical records. ECMO denotes extracorporeal membrane oxygenation, CRP C-Reactive protein, AST Aspartate transaminase ALT Alanine transaminase, ECG electrocardiography, ARDS acute respiratory distress syndrome and IQR interquartile range. ¥ These medications were part of standard care therapy as per Clinical Management Guidelines for COVID-

¹⁹ by Ministry of National Health Services, Pakistan.

 $[\]P$ Medical doctors, nurses and paramedics

Table S2. Distribution of severity of cough over time*

								N	Number of Da	ays					
			1	2	3	4	5	6	7	8	9	10	11	12	13
		None€	45	44	48 (46.6)	43	47	58 (56.31)	68 (66.02)	83 (80.58)	91	92 (89.32)	97	99	99
	te		(43.69)	(42.72)	, ,	(41.75)	(45.63)	, , ,	, , ,	, ,	(88.35)		(94.17)	(96.12)	(97.06)
one	Moderate	Mild ^b	9 (8.74)	11 (10.68)	18 (17.48)	31 (30.1)	31 (30.1)	30 (29.13)	25 (24.27)	13 (12.62)	8 (7.77)	7 (6.8)	3 (2.91)	2 (1.94)	1 (0.98)
AI	M	Moderate ^ф	43	42	33	29	24 (23.3)	15 (14.56)	10 (9.71)	7 (6.8)	3 (2.91)	4 (3.88)	3 (2.91)	2 (1.94)	1 (0.98)
are			(41.75)	(40.78)	(32.04)	(28.16)	, ,	,		, ,	, ,		, ,	, ,	, ,
Standard Care Alone		Severe ²	6 (5.83)	6 (5.83)	4 (3.88)	0 (0)	1 (0.97)	0 (0)	0 (0)	0 (0)	1 (0.97)	0 (0)	0 (0)	0 (0)	1 (0.98)
dar		None€	10	8 (15.09)	7 (13.21)	6 (11.32)	14	16 (30.19)	18 (35.29)	26 (50.98)	26	29 (59.18)	29 (61.7)	34	36
tan			(18.87)	, ,	, ,	,	(26.42)	,		,	(53.06)			(73.91)	(78.26)
S	ere	Mild th	0 (0)	1 (1.89)	2 (3.77)	9 (16.98)	8 (15.09)	17 (32.08)	14 (27.45)	8 (15.69)	14 (28.57)	7 (14.29)	4 (8.51)	4 (8.7)	5 (10.87)
	Severe	Moderate ^φ	15 (28.3)	24	26	22	23 (43.4)	13 (24.53)	16 (31.37)	15 (29.41)	9 (18.37)	11 (22.45)	10	5 (10.87)	5 (10.87)
	• •			(45.28)	(49.06)	(41.51)							(21.28)		
		Severe ^{\Sigma}	28	20	18	16	8 (15.09)	7 (13.21)	3 (5.88)	2 (3.92)	0 (0)	2 (4.08)	4 (8.51)	3 (6.52)	0 (0)
			(52.83)	(37.74)	(33.96)	(30.19)									
		None [€]	42	41	51	66	75	105	105	105	107	106	104	107	107
	ه	7.507 t dt	(39.25)	(38.32)	(47.66)	(61.68)	(70.09)	(98.13)	(98.13)	(98.13)	(100)	(99.07)	(97.2)	(100)	(100)
va	Moderate	Mild ^b	5 (4.67)	11 (10.28)	30 (28.04)	34 (31.78)	31 (28.97)	2 (1.87)	2 (1.87)	2 (1.87)	0 (0)	1 (0.93)	3 (2.8)	0 (0)	0 (0)
Sati	Tod	Moderate ^φ	53	50	25	7 (6.54)	1 (0.93)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
la		2	(49.53)	(46.73)	(23.36)										
igel		Severe ²	7 (6.54)	5 (4.67)	1 (0.93)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
y-N		None [€]	10 (20)	9 (18)	14 (28)	13 (26)	22 (44)	30 (60)	36 (72)	38 (76)	39 (78)	44 (88)	40 (80)	46 (92)	45 (90)
Honey-Nigella Sativa	ere	Mild th	7 (14)	4 (8)	3 (6)	15 (30)	14 (28)	8 (16)	7 (14)	5 (10)	6 (12)	2 (4)	4 (8)	0 (0)	0 (0)
~	Severe	Moderate ^ф	10 (20)	20 (40)	26 (52)	19 (38)	10 (20)	10 (20)	4 (8)	7 (14)	4 (8)	4 (8)	5 (10)	3 (6)	5 (10)
		Severe ²	23 (46)	17 (34)	7 (14)	3 (6)	4 (8)	2 (4)	3 (6)	0 (0)	1 (2)	0 (0)	1 (2)	1 (2)	0 (0)

^{*} Data are presented as no. (%) unless indicated otherwise. Cough is classified as mild, moderate and severe, €No cough, **do** occasional/transient cough, **qo** frequent cough, slightly influencing day time activities, ∑ frequent cough, significantly influencing daytime activities

Table S3. Distribution of Severity of Symptoms over time*

								•	Number of	Days					
			1	2	3	4	5	6	7	8	9	10	11	12	13
	9	None [€]	0 (0)	0 (0)	3 (2.91)	5 (4.85)	9 (8.74)	29 (28.16)	39 (37.86)	58 (56.31)	67 (65.05)	77 (74.76)	97 (94.17)	97 (94.17)	99 (96.12)
one	Moderate	Mild th	2 (1.94)	3 (2.91)	9 (8.74)	23 (22.33)	40 (38.83)	36 (34.95)	32 (31.07)	18 (17.48)	24 (23.3)	22 (21.36)	2 (1.94)	2 (1.94)	0 (0)
re Al	Mo	Moderate ^ф	91	91	81	67	45	29 (28.16)	24 (23.3)	21 (20.39)	8 (7.77)	0 (0)	0 (0)	0 (0)	0 (0)
Standard Care Alone		Severe ²	(88.35) 10 (9.71)	(88.35) 9 (8.74)	(78.64) 10 (9.71)	(65.05) 8 (7.77)	(43.69) 9 (8.74)	9 (8.74)	8 (7.77)	6 (5.83)	4 (3.88)	4 (3.88)	4 (3.88)	4 (3.88)	4 (3.88)
ında		None [€]	0 (0)	0 (0)	0 (0)	1 (1.89)	0 (0)	5 (9.62)	6 (11.76)	10 (19.61)	14 (28)	19 (38)	24 (50)	24 (50)	27 (56.25)
Ste	re	Mild th	0 (0)	0 (0)	1 (1.89)	2 (3.77)	4 (7.69)	4 (7.69)	13 (25.49)	15 (29.41)	9 (18)	5 (10)	0 (0)	4 (8.33)	3 (6.25)
	Severe	Moderate ^{\$\phi\$}	0 (0)	2 (3.77)	7 (13.21)	15 (28.3)	24 (46.15)	16 (30.77)	8 (15.69)	4 (7.84)	12 (24)	9 (18)	13 (27.08)	7 (14.58)	9 (18.75)
		Severe ²	53 (100)	51 (96.23)	45 (84.91)	35 (66.04)	24 (46.15)	27 (51.92)	24 (47.06)	22 (43.14)	15 (30)	17 (34)	11 (22.92)	13 (27.08)	9 (18.75)
		None [€]	0 (0)	0 (0)	4 (3.74)	43 (40.19)	60 (56.07)	101 (94.39)	104 (97.2)	105 (98.13)	107 (100)	106 (99.07)	106 (99.07)	107 (100)	106 (99.07)
va	erate	Mild th	2 (1.87)	9 (8.41)	52 (48.6)	45 (42.06)	41 (38.32)	5 (4.67)	2 (1.87)	2 (1.87)	0 (0)	1 (0.93)	1 (0.93)	0 (0)	1 (0.93)
Honey-Nigella Sativa	Moderate	Moderate ^ф	98 (91.59)	93 (86.92)	50 (46.73)	18 (16.82)	5 (4.67)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
igell		Severe ²	7 (6.54)	5 (4.67)	1 (0.93)	1 (0.93)	1 (0.93)	1 (0.93)	1 (0.93)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
sy-N		None [€]	0 (0)	0 (0)	0 (0)	1 (2)	6 (12)	24 (48)	28 (56)	35 (70)	39 (78)	41 (82)	41 (82)	41 (82)	41 (82)
Нопа	ere	Mild th	0 (0)	0 (0)	1 (2)	13 (26)	21 (42)	12 (24)	13 (26)	7 (14)	2 (4)	0 (0)	0 (0)	0 (0)	0 (0)
7	Severe	Moderate ^φ	0 (0)	6 (12)	24 (48)	24 (48)	16 (32)	9 (18)	2 (4)	2 (4)	6 (12)	3 (6)	5 (10)	5 (10)	5 (10)
		Severe ²	50 (100)	44 (88)	25 (50)	12 (24)	7 (14)	5 (10)	7 (14)	6 (12)	3 (6)	6 (12)	4 (8)	4 (8)	4 (8)

^{*}Data are presented as no. (%) unless indicated otherwise. Severity of symptoms is classified as mild, moderate and severe. € No symptoms, **b** symptoms of an upper respiratory tract viral infection i.e. low grade fever, dry cough, sore throat, nasal congestion, malaise but no radiological evidence of pneumonia **p** Moderate disease includes patients with Hypoxia (Oxygen saturation <94% but >90%) or chest X-ray with infiltrates involving <50% of the lung fields or fever, cough, sputum production, and other respiratory tract or non-specific symptoms along with manifestation of pneumonia on imaging but no signs of severe pneumonia, **\(\Sigma\)** Fever is associated with severe dyspnoea, respiratory distress, tachypnea (> 30 breaths/min), and hypoxia (SpO2 < 94% on room air)" or a PaO2 to FiO2 ratio of 300 or lower.

Table S4. Distribution of fever over time*

								N	Number of Da	ays					
			1	2	3	4	5	6	7	8	9	10	11	12	13
	به	None [€]	1 (0.97)	1 (0.97)	1 (0.97)	4 (3.88)	14 (13.59)	37 (35.92)	46 (44.66)	63 (61.17)	72 (69.9)	87 (84.47)	96 (93.2)	101 (98.06)	102 (99.03)
one	Moderate	Mild th	0 (0)	7 (6.8)	14 (13.59)	30 (29.13)	47 (45.63)	29 (28.16)	36 (34.95)	24 (23.3)	23 (22.33)	10 (9.71)	5 (4.85)	0 (0)	0 (0)
Standard Care Alone	Me	Moderate ^ф	90 (87.38)	86 (83.5)	81 (78.64)	60 (58.25)	36 (34.95)	33 (32.04)	19 (18.45)	15 (14.56)	8 (7.77)	6 (5.83)	2 (1.94)	2 (1.94)	1 (0.97)
ard C		Severe ²	12 (11.65)	9 (8.74)	7 (6.8)	9 (8.74)	6 (5.83)	4 (3.88)	2 (1.94)	1 (0.97)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Stand		None [€]	3 (5.66)	3 (5.66)	3 (5.66)	2 (3.77)	6 (11.54)	11 (21.15)	16 (31.37)	19 (37.25)	21 (42.86)	26 (53.06)	30 (63.83)	32 (69.57)	34 (73.91)
	Severe	Mild ^b	0 (0)	0 (0)	1 (1.89)	12 (22.64)	9 (17.31)	7 (13.46)	10 (19.61)	11 (21.57)	12 (24.49)	6 (12.24)	2 (4.26)	5 (10.87)	6 (13.04)
	Sev	Moderate ^φ	6 (11.32)	11 (20.75)	28 (52.83)	23 (43.4)	23 (44.23)	25 (48.08)	19 (37.25)	14 (27.45)	13 (26.53)	12 (24.49)	12 (25.53)	8 (17.39)	6 (13.04)
		Severe ²	44 (83.02)	39 (73.58)	21 (39.62)	16 (30.19)	14 (26.92)	9 (17.31)	6 (11.76)	7 (13.73)	3 (6.12)	5 (10.2)	3 (6.38)	1 (2.17)	0 (0)
		None [€]	4 (3.74)	4 (3.74)	9 (8.41)	63 (58.88)	80 (74.77)	100 (93.46)	101 (94.39)	107 (100)	107 (100)	107 (100)	107 (100)	107 (100)	107 (100)
ı a	Moderate	Mild th	0 (0)	19 (17.76)	67 (62.62)	31 (28.97)	21 (19.63)	6 (5.61)	5 (4.67)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Honey-Nigella Sativa	Mod	Moderate ^ф	96 (89.72)	80 (74.77)	30 (28.04)	12 (11.21)	6 (5.61)	1 (0.93)	1 (0.93)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
igella		Severe ^{\Sigma}	7 (6.54)	4 (3.74)	1 (0.93)	1 (0.93)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
ey-Ni		None [€]	2 (4)	2 (4)	2 (4)	11 (22)	17 (34)	31 (62)	32 (64)	35 (70)	40 (80)	44 (88)	47 (94)	47 (94)	49 (98)
Hon	Severe	Mild ^b	0 (0)	0 (0)	7 (14)	13 (26)	20 (40)	8 (16)	11 (22)	7 (14)	2 (4)	0 (0)	0 (0)	0 (0)	0 (0)
	Sev	Moderate ^ф	3 (6)	24 (48)	28 (56)	24 (48)	10 (20)	8 (16)	6 (12)	6 (12)	6 (12)	4 (8)	2 (4)	2 (4)	1 (2)
		Severe ²	45 (90)	24 (48)	13 (26)	2 (4)	3 (6)	3 (6)	1 (2)	2 (4)	2 (4)	2 (4)	1 (2)	1 (2)	0 (0)

^{*} Data are presented as no. (%) unless indicated otherwise and fever is classified as mild, moderate and severe, $\[\in \]$ 98-99 °F, $\[\mathbf{d} \]$ <100 °F, $\[\mathbf{\phi} \]$ 100-101.9 °F, $\[\mathbf{\Sigma} \]$ ≥ 102°F

 Table S5. Distribution of Myalgia over time*

								N	umber of I	Days					
			1	2	3	4	5	6	7	8	9	10	11	12	13
		None [€]	40	42	38	47	47	65	73	76	84	99	96 (93.2)	101	101
	te		(38.83)	(40.78)	(36.89)	(45.63)	(45.63)	(63.11)	(70.87)	(73.79)	(81.55)	(96.12)		(98.06)	(98.06)
6)	Moderate	Mild th	9 (8.74)	9 (8.74)	25	27	29	19	23	20	14	0 (0)	5 (4.85)	0 (0)	0 (0)
one	po				(24.27)	(26.21)	(28.16)	(18.45)	(22.33)	(19.42)	(13.59)				
Alone	Z	Moderate ^ф	49	49	36	26	27	19	7 (6.8)	6 (5.83)	4 (3.88)	3 (2.91)	1 (0.97)	1 (0.97)	2 (1.94)
Care			(47.57)	(47.57)	(34.95)	(25.24)	(26.21)	(18.45)							
		Severe ^{\Sigma}	5 (4.85)	3 (2.91)	4 (3.88)	3 (2.91)	0 (0)	0 (0)	0 (0)	1 (0.97)	1 (0.97)	1 (0.97)	1 (0.97)	1 (0.97)	0 (0)
ırd		None [€]	19	19	17	18	21	19	24	25	31	32	37	42 (91.3)	42 (91.3)
Standard			(35.85)	(35.85)	(32.08)	(33.96)	(40.38)	(36.54)	(47.06)	(49.02)	(63.27)	(65.31)	(78.72)		
Sta	ده	Mild th	0(0)	0 (0)	8 (15.09)	9 (16.98)	6 (11.54)	9 (17.31)	11	7 (13.73)	8 (16.33)	7 (14.29)	6 (12.77)	3 (6.52)	3 (6.52)
	er.								(21.57)						
	Severe	Moderate ^ф	24	20	19	23 (43.4)	19	17	10	18	9 (18.37)	10	4 (8.51)	1 (2.17)	1 (2.17)
			(45.28)	(37.74)	(35.85)		(36.54)	(32.69)	(19.61)	(35.29)		(20.41)			
		Severe ²	10	14	9 (16.98)	3 (5.66)	6 (11.54)	7 (13.46)	6 (11.76)	1 (1.96)	1 (2.04)	0 (0)	0 (0)	0 (0)	0 (0)
			(18.87)	(26.42)											
		None $^{\epsilon}$	58	54	67	78 (72.9)	95	104	107	107	107	104	107	107 (100)	105
<i>a</i>	به		(54.21)	(50.47)	(62.62)		(88.79)	(97.2)	(100)	(100)	(100)	(97.2)	(100)		(98.13)
ţiv	rat	Mild th	9 (8.41)	28	31	25	11	3 (2.8)	0 (0)	0 (0)	0 (0)	3 (2.8)	0 (0)	0 (0)	2 (1.87)
Sativa	Moderate			(26.17)	(28.97)	(23.36)	(10.28)								
lla	Mo	Moderate ^ф	38	23 (21.5)	8 (7.48)	3 (2.8)	1 (0.93)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0(0)	0 (0)
ige	, ,		(35.51)												
\ \frac{1}{N}		Severe ^S	2 (1.87)	2 (1.87)	1 (0.93)	1 (0.93)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
nes	ده	None€	19 (38)	18 (36)	19 (38)	27 (54)	36 (72)	40 (80)	44 (88)	45 (90)	46 (92)	45 (90)	47 (94)	48 (96)	47 (94)
Honey-Nigella	ver	Mild th	1 (2)	3 (6)	9 (18)	11 (22)	6 (12)	3 (6)	0 (0)	1 (2)	1 (2)	2 (4)	1 (2)	1 (2)	0 (0)
	Severe	Moderate ^ф	18 (36)	18 (36)	19 (38)	11 (22)	5 (10)	7 (14)	4 (8)	3 (6)	2 (4)	3 (6)	2 (4)	1 (2)	3 (6)
		Severe ²	12 (24)	11 (22)	3 (6)	1 (2)	3 (6)	0 (0)	2 (4)	1 (2)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)

^{*} Data are presented as no. (%) unless indicated otherwise. Myalgia is classified as mild, moderate and severe on subjective basis. Patients have been provided with a scale of 1-10, with 1 being the lowest and 10 being the highest value.

€No Myalgia **do** 1-3 **qo** 4-6 **Σ** >6-10

Table S6. Distribution of Shortness of Breath over time*

								N	umber of Da	ays					
			1	2	3	4	5	6	7	8	9	10	11	12	13
	47	None [€]	99	102	99	95	93	91	94	94	96 (93.2)	94	96 (93.2)	99	99 (96.12)
	ate		(96.12)	(99.03)	(96.12)	(92.23)	(90.29)	(88.35)	(91.26)	(91.26)		(91.26)		(96.12)	
0)	der	Mild th	2 (1.94)	1 (0.97)	1 (0.97)	3 (2.91)	4 (3.88)	6 (5.83)	3 (2.91)	3 (2.91)	3 (2.91)	3 (2.91)	4 (3.88)	0 (0)	0 (0)
Alone	Moderate	Moderate ^{\phi}	2 (1.94)	0 (0)	3 (2.91)	1 (0.97)	2 (1.94)	1 (0.97)	1 (0.97)	0 (0)	0 (0)	3 (2.91)	0 (0)	0 (0)	0 (0)
Al		Severe ^{\Sigma}	0 (0)	0 (0)	0 (0)	4 (3.88)	4 (3.88)	5 (4.85)	5 (4.85)	5 (4.85)	3 (2.91)	2 (1.94)	2 (1.94)	3 (2.91)	3 (2.91)
Care		Very Severe [¥]	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (0.97)	1 (0.97)	1 (0.97)	1 (0.97)	1 (0.97)	1 (0.97)
\mathcal{C}		None [€]	0 (0)	1 (1.89)	1 (1.89)	7 (14)	7 (13.46)	12	13	22 (44.9)	24 (50)	23	24	25	28 (63.64)
ırd								(26.09)	(25.49)			(46.94)	(53.33)	(56.82)	
Standard		Mild th	3 (5.66)	3 (5.66)	8 (15.09)	7 (14)	6 (11.54)	4 (8.7)	9 (17.65)	3 (6.12)	0 (0)	1 (2.04)	0 (0)	2 (4.55)	3 (6.82)
Sta	re	Moderate ^o	18	16	12	10 (20)	17	16	8 (15.69)	4 (8.16)	5 (10.42)	5 (10.2)	6 (13.33)	7 (15.91)	4 (9.09)
	Severe		(33.96)	(30.19)	(22.64)		(32.69)	(34.78)							
	Š	Severe ²	17	18	17	12 (24)	6 (11.54)	3 (6.52)	6 (11.76)	8 (16.33)	7 (14.58)	9 (18.37)	10	6 (13.64)	5 (11.36)
			(32.08)	(33.96)	(32.08)								(22.22)		
		Very Severe [¥]	15 (28.3)	15 (28.3)	15 (28.3)	14 (28)	16	11	15	12	12 (25)	11	5 (11.11)	4 (9.09)	4 (9.09)
							(30.77)	(23.91)	(29.41)	(24.49)		(22.45)			
		None€	106	106	105	106	105	106	106	107 (100)	107 (100)	106	106	106	106
2	ıte		(99.07)	(99.07)	(98.13)	(99.07)	(98.13)	(99.07)	(99.07)			(99.07)	(99.07)	(99.07)	(99.07)
Sativa	era	Mild th	0 (0)	1 (0.93)	2 (1.87)	1 (0.93)	2 (1.87)	1 (0.93)	1 (0.93)	0 (0)	0 (0)	1 (0.93)	1 (0.93)	1 (0.93)	1 (0.93)
	Moderate	Moderate ^ф	1 (0.93)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
lla	\mathbf{z}	Severe ^{\Sigma}	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
ige		Very Severe [¥]	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
\ \frac{1}{2}		None [€]	0 (0)	1 (2)	1 (2)	17 (34)	23 (46)	35 (70)	35 (70)	37 (74)	40 (80)	40 (80)	41 (82)	41 (82)	41 (82)
nes	re	Mild th	2 (4)	3 (6)	18 (36)	13 (26)	11 (22)	4 (8)	5 (10)	5 (10)	1 (2)	1 (2)	1 (2)	1 (2)	2 (4)
Honey-Nigella	Severe	Moderate ^ф	21 (42)	24 (48)	13 (26)	11 (22)	8 (16)	3 (6)	2 (4)	1 (2)	3 (6)	3 (6)	4 (8)	5 (10)	4 (8)
	Š	Severe ^{\Sigma}	19 (38)	14 (28)	10 (20)	2 (4)	2 (4)	1 (2)	2 (4)	2 (4)	1 (2)	4 (8)	2 (4)	1 (2)	0 (0)
		Very Severe [¥]	8 (16)	8 (16)	8 (16)	7 (14)	6 (12)	7 (14)	6 (12)	5 (10)	5 (10)	2 (4)	2 (4)	2 (4)	3 (6)

^{*} Data are presented as no. (%) unless indicated otherwise. Shortness of breath is classified as Grade1, Grade2, Grade3, Grade4 and Grade5.

[€] Grade1 (none)=Not troubled by breathlessness except on strenuous exercise, **d** Grade 2 (mild)=Short of breath when hurrying on the level or walking up a slight hill, **\phi** Grade 3 (moderate)=Walks slower than most people on the level, stops after a mile or so, or stop after 15 minutes walking at own pace, Σ Grade 4 (severe)=Stops for breath after walking about 100yds or a few minutes on level ground \mathbb{\cupa}\$ Grade 5 (very severe)=Too breathless to leave the house, or breathless when undressing

 Table S7 Variation of oxygen saturation over days*

No. of days	Honey and Nigella Sativa with Standard of care	Standard of care alone
1	80.92	80.91
2	83.32	80.68
3	84.70	81.45
4	88.52	82.38
5	90.92	83.81
6	92.64	84.18
7	93.52	85.52
8	94.14	86.96
9	94.62	88.33
10	95.14	88.22
11	95.72	90.72
12	95.70	89.39
13	95.46	91.50

^{*}oxygen saturation is given in percentage unless indicated otherwise.

Table S8. Distribution of How sick do you feel over time*

									Number of	Days					
			1	2	3	4	5	6	7	8	9	10	11	12	13
	te	None [€]	0 (0)	4 (3.88)	1 (0.97)	8 (7.77)	11 (10.68)	28 (27.18)	44 (42.72)	61 (59.22)	77 (74.76)	81 (78.64)	90 (87.38)	97 (94.17)	98 (95.15)
lone	Moderate	Mild ^b	0 (0)	0 (0)	7 (6.8)	23 (22.33)	42 (40.78)	39 (37.86)	29 (28.16)	24 (23.3)	11 (10.68)	11 (10.68)	7 (6.8)	2 (1.94)	1 (0.97)
are A	M	Moderate [®]	91 (88.35)	91 (88.35)	88 (85.44)	67 (65.05)	44 (42.72)	28 (27.18)	24 (23.3)	12 (11.65)	11 (10.68)	8 (7.77)	3 (2.91)	0 (0)	1 (0.97)
Standard Care Alone		Severe ^{\Sigma}	12 (11.65)	8 (7.77)	7 (6.8)	5 (4.85)	6 (5.83)	8 (7.77)	6 (5.83)	6 (5.83)	4 (3.88)	3 (2.91)	3 (2.91)	4 (3.88)	3 (2.91)
Stana		None [€]	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	5 (9.8)	6 (12)	11 (21.57)	14 (28.57)	19 (38.78)	22 (46.81)	26 (56.52)	28 (60.87)
	Severe	Mild ^b	0 (0)	0 (0)	1 (1.92)	7 (13.46)	8 (15.69)	8 (15.69)	14 (28)	16 (31.37)	12 (24.49)	5 (10.2)	4 (8.51)	2 (4.35)	2 (4.35)
	Sev	Moderate ^ф	1 (1.92)	6 (11.54)	8 (15.38)	13 (25)	21 (41.18)	15 (29.41)	8 (16)	1 (1.96)	5 (10.2)	7 (14.29)	5 (10.64)	9 (19.57)	6 (13.04)
		Severe ^{\Sigma}	51 (98.08)	46 (88.46)	43 (82.69)	32 (61.54)	22 (43.14)	23 (45.1)	22 (44)	23 (45.1)	18 (36.73)	18 (36.73)	16 (34.04)	9 (19.57)	10 (21.74)
		None [€]	2 (1.87)	2 (1.87)	6 (5.61)	48 (44.86)	58 (54.21)	98 (91.59)	102 (95.33)	104 (97.2)	106 (99.07)	106 (99.07)	106 (99.07)	106 (99.07)	106 (99.07)
	erate	Mild th	0 (0)	10 (9.35)	54 (50.47)	40 (37.38)	44 (41.12)	7 (6.54)	3 (2.8)	3 (2.8)	1 (0.93)	1 (0.93)	1 (0.93)	1 (0.93)	1 (0.93)
Honey-Nigella Sativa	Moderate	Moderate ^{ϕ}	98 (91.59)	90 (84.11)	46 (42.99)	19 (17.76)	5 (4.67)	2 (1.87)	2 (1.87)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
gella		Severe ²	7 (6.54)	5 (4.67)	1 (0.93)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
ey-Nig		None [€]	0 (0)	0 (0)	0 (0)	3 (6)	7 (14)	24 (48)	30 (60)	35 (70)	39 (78)	41 (82)	40 (80)	41 (82)	41 (82)
Hone	ere	Mild th	0 (0)	0 (0)	2 (4)	11 (22)	23 (46)	13 (26)	7 (14)	7 (14)	2 (4)	0 (0)	1 (2)	0 (0)	0 (0)
	Severe	Moderate ^ф	3 (6)	12 (24)	21 (42)	23 (46)	13 (26)	5 (10)	6 (12)	3 (6)	3 (6)	4 (8)	2 (4)	4 (8)	4 (8)
		Severe ^{\Sigma}	47 (94)	38 (76)	27 (54)	13 (26)	7 (14)	8 (16)	7 (14)	5 (10)	6 (12)	5 (10)	7 (14)	5 (10)	5 (10)

^{*} Data are presented as no. (%) unless indicated otherwise. Responses to "How sick do you feel" are classified as mild, moderate and severe on subjective basis. Patients have been provided with a scale of 1-10, with 1 being the highest and 10 being the lowest

[€] patient is healthy/usual state of health $db > 6 qp 4-6 \Sigma 1-3$

Table S9 Variation in emotional status over time*

								N	umber of Da	ays					
		RYES	1	2	3	4	5	6	7	8	9	10	11	12	13
		1	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
		2	0 (0)	0 (0)	2 (1.94)	2 (1.94)	2 (1.94)	2 (1.94)	2 (1.94)	2 (1.94)	1 (0.97)	1 (0.97)	1 (0.97)	1 (0.97)	0 (0)
		3	0 (0)	0 (0)	0 (0)	4 (3.88)	5 (4.85)	8 (7.77)	0 (0)	1 (0.97)	3 (2.91)	1 (0.97)	0 (0)	0 (0)	3 (2.91)
		4	31 (30.1)	29	24 (23.3)	20	9 (8.74)	3 (2.91)	2 (1.94)	1 (0.97)	0 (0)	1 (0.97)	2 (1.94)	3 (2.91)	1 (0.97)
			` ,	(28.16)	` ′	(19.42)	` ,	` ,	, ,	` ,	` '	` ,	` ′	` ,	` ′
	ate	5	62	59	48 (46.6)	20	12	3 (2.91)	8 (7.77)	2 (1.94)	0 (0)	1 (0.97)	1 (0.97)	0 (0)	0 (0)
]er:		(60.19)	(57.28)		(19.42)	(11.65)			2 (2 2 1)				2 (2)	
	Moderate	6	10 (9.71)	11	15	26	28	19	11	3 (2.91)	4 (3.88)	2 (1.94)	1 (0.97)	0 (0)	0 (0)
		7	0 (0)	(10.68) 4 (3.88)	(14.56) 9 (8.74)	(25.24) 24 (23.3)	(27.18)	(18.45)	(10.68)	16	6 (5.83)	2 (1.94)	1 (0.97)	0 (0)	0 (0)
		/	0 (0)	4 (3.88)	9 (6.74)	24 (23.3)	(25.24)	(28.16)	(19.42)	(15.53)	0 (3.83)	2 (1.94)	1 (0.97)	0 (0)	0 (0)
		8	0 (0)	0 (0)	5 (4.85)	2 (1.94)	12	9 (8.74)	17 (16.5)	15	14	8 (7.77)	2 (1.94)	2 (1.94)	0 (0)
Alone			0 (0)	0 (0)	(1130)	_ (117.1)	(11.65)) (01/1)	17 (13.6)	(14.56)	(13.59)	0 (/1//)	_ (11) 1)	_ (11) 1)	
All		9	0 (0)	0 (0)	0 (0)	5 (4.85)	5 (4.85)	21	16	16	10 (9.71)	11	5 (4.85)	5 (4.85)	6 (5.83)
are								(20.39)	(15.53)	(15.53)		(10.68)			
Standard Care		10	0 (0)	0 (0)	0 (0)	0 (0)	4 (3.88)	9 (8.74)	27	47	65	76	90	92	93
dar		-	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	(26.21)	(45.63)	(63.11)	(73.79)	(87.38)	(89.32)	(90.29)
anc		1	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (4.08)	2 (4.08)	0 (0)	0 (0)	0 (0)
Sı		2	3 (5.66)	2 (3.77)	4 (7.55)	5 (9.43)	4 (7.69)	3 (5.77)	5 (9.8)	4 (7.84)	2 (4.08)	0 (0)	0 (0)	0 (0)	0 (0)
		3	7 (13.21)	13	16	18	11	14	10	8 (15.69)	5 (10.2)	5 (10.2)	5 (10.64)	4 (8.7)	2 (4.35)
			26	(24.53)	(30.19)	(33.96)	(21.15)	(26.92)	(19.61)	0 (17 (0)	C (10.04)	0 (10 27)	11 (22 4)	0 (17 20)	2 (5 52)
		4	26	28	22	5 (9.43)	8 (15.38)	5 (9.62)	8 (15.69)	8 (15.69)	6 (12.24)	9 (18.37)	11 (23.4)	8 (17.39)	3 (6.52)
		5	(49.06) 12	(52.83) 9 (16.98)	(41.51) 8 (15.09)	14	10	4 (7.69)	3 (5.88)	3 (5.88)	9 (18.37)	1 (2.04)	1 (2.13)	1 (2.17)	6 (13.04)
	ere		(22.64)) (10.70)	0 (13.07)	(26.42)	(19.23)	1 (7.07)	3 (3.66)	3 (3.00)) (10.57)	1 (2.04)	1 (2.13)	1 (2.17)	0 (13.04)
	Severe	6	5 (9.43)	0 (0)	3 (5.66)	8 (15.09)	14	12	4 (7.84)	3 (5.88)	1 (2.04)	8 (16.33)	4 (8.51)	1 (2.17)	3 (6.52)
			, , ,	` ,	, , ,	,	(26.92)	(23.08)	, , ,	, , ,		,	, ,	, ,	, , ,
		7	0 (0)	1 (1.89)	0 (0)	3 (5.66)	1 (1.92)	9 (17.31)	10	5 (9.8)	3 (6.12)	1 (2.04)	1 (2.13)	3 (6.52)	1 (2.17)
									(19.61)						
		8	0 (0)	0 (0)	0 (0)	0 (0)	4 (7.69)	1 (1.92)	6 (11.76)	9 (17.65)	7 (14.29)	4 (8.16)	1 (2.13)	2 (4.35)	2 (4.35)
		9	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	4 (7.69)	1 (1.96)	4 (7.84)	4 (8.16)	5 (10.2)	2 (4.26)	3 (6.52)	2 (4.35)
		10	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	4 (7.84)	7 (13.73)	10	14	22	24	27 (58.7)
											(20.41)	(28.57)	(46.81)	(52.17)	

		1	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
		2	0 (0)	2 (1.87)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
		3	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
		4	17 (15.89)	14 (13.08)	8 (7.48)	5 (4.67)	2 (1.87)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	Moderate	5	70 (65.42)	57 (53.27)	22 (20.56)	7 (6.54)	4 (3.74)	2 (1.87)	1 (0.93)	0 (0)	0 (0)	0 (0)	1 (0.93)	1 (0.93)	1 (0.93)
	Iode	6	19 (17.76)	26 (24.3)	29 (27.1)	13 (12.15)	6 (5.61)	1 (0.93)	0 (0)	0 (0)	0 (0)	1 (0.93)	0 (0)	0 (0)	0 (0)
	N	7	1 (0.93)	7 (6.54)	33 (30.84)	25 (23.36)	11 (10.28)	5 (4.67)	3 (2.8)	2 (1.89)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
va		8	0 (0)	1 (0.93)	12 (11.21)	23 (21.5)	22 (20.56)	2 (1.87)	3 (2.8)	3 (2.83)	2 (1.87)	0 (0)	0 (0)	0 (0)	0 (0)
Sati		9	0 (0)	0 (0)	3 (2.8)	27 (25.23)	20 (18.69)	28 (26.17)	7 (6.54)	7 (6.6)	0 (0)	2 (1.87)	0 (0)	0 (0)	1 (0.93)
Honey-Nigella Sativa		10	0 (0)	0 (0)	0 (0)	7 (6.54)	42 (39.25)	69 (64.49)	93 (86.92)	94 (88.68)	105 (98.13)	104 (97.2)	106 (99.07)	106 (99.07)	105 (98.13)
v-Ni		1	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
one		2	1 (2)	1 (2)	1 (2)	2 (4)	2 (4)	4 (8)	0 (0)	1 (2)	1 (2)	2 (4)	0 (0)	2 (4)	2 (4)
H		3	13 (26)	8 (16)	7 (14)	6 (12)	5 (10)	3 (6)	6 (12)	3 (6)	1 (2)	0 (0)	2 (4)	0 (0)	1 (2)
		4	26 (52)	30 (60)	4 (8)	3 (6)	1 (2)	1 (2)	2 (4)	4 (8)	6 (12)	6 (12)	6 (12)	6 (12)	0 (0)
	ere	5	9 (18)	5 (10)	20 (40)	2 (4)	1 (2)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	6 (12)
	Severe	6	1 (2)	3 (6)	13 (26)	19 (38)	7 (14)	2 (4)	2 (4)	0 (0)	1 (2)	1 (2)	1 (2)	0 (0)	0 (0)
		7	0 (0)	3 (6)	3 (6)	12 (24)	15 (30)	4 (8)	2 (4)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
		8	0 (0)	0 (0)	2 (4)	3 (6)	12 (24)	15 (30)	11 (22)	3 (6)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)
		9	0 (0)	0 (0)	0 (0)	3 (6)	5 (10)	14 (28)	9 (18)	8 (16)	3 (6)	1 (2)	0 (0)	0 (0)	0 (0)
		10	0 (0)	0 (0)	0 (0)	0 (0)	2 (4)	6 (12)	18 (36)	30 (60)	37 (74)	40 (80)	41 (82)	41 (82)	41 (82)

^{*}Data are presented as no. (%) unless indicated otherwise. Self-ratings on "Rate your emotional status (RYES)" by patients are classified on subjective basis. Patients have been provided with a scale of 1-10, with 1 being the lowest and 10 being the highest

Table S10 Variation of clinical status grading over days*

					Number of Days			
		CGS	0	4	6	8	10	12
	4)	1	0 (0)	2 (1.94)	11 (10.68)	36 (34.95)	71 (68.93)	98 (95.15)
	ate	2	68 (66.02)	54 (52.43)	51 (49.51)	50 (48.54)	26 (25.24)	1 (0.97)
e l	Moderate	3	35 (33.98)	42 (40.78)	35 (33.98)	12 (11.65)	2 (1.94)	0 (0)
Alone	√Io I	4	0 (0)	4 (3.88)	4 (3.88)	1 (0.97)	2 (1.94)	1 (0.97)
e A		5	0 (0)	0 (0)	2 (1.94)	3 (2.91)	1 (0.97)	2 (1.94)
Care		6	0 (0)	1 (0.97)	0 (0)	1 (0.97)	1 (0.97)	1 (0.97)
) p.		7	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Standard		1	0 (0)	0 (0)	1 (1.89)	8 (15.09)	10 (18.87)	24 (45.28)
an		2	0 (0)	0 (0)	1 (1.89)	1 (1.89)	13 (24.53)	0 (0)
S	อ	3	0 (0)	3 (5.66)	10 (18.87)	17 (32.08)	2 (3.77)	2 (3.77)
	Severe	4	23 (43.4)	24 (45.28)	23 (43.4)	12 (22.64)	16 (30.19)	13 (24.53)
	Š	5	30 (56.6)	22 (41.51)	13 (24.53)	9 (16.98)	4 (7.55)	4 (7.55)
		6	0 (0)	3 (5.66)	3 (5.66)	3 (5.66)	4 (7.55)	3 (5.66)
		7	0 (0)	1 (1.89)	2 (3.77)	3 (5.66)	4 (7.55)	7 (13.21)
		1	0 (0)	25 (23.36)	68 (63.55)	97 (90.65)	103 (96.26)	106 (99.07)
	d)	2	71 (66.36)	67 (62.62)	35 (32.71)	9 (8.41)	3 (2.8)	0 (0)
	Moderate	3	36 (33.64)	14 (13.08)	3 (2.8)	1 (0.93)	0 (0)	0 (0)
na A	- 	4	0 (0)	1 (0.93)	1 (0.93)	0 (0)	1 (0.93)	1 (0.93)
ati	Λο	5	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
a S		6	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
rell		7	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Vig		1	0 (0)	2 (4)	14 (28)	29 (58)	39 (78)	41 (82)
Honey-Nigella Sativa		2	0 (0)	1 (2)	11 (22)	10 (20)	2 (4)	1 (2)
ouo	re	3	0 (0)	20 (40)	13 (26)	4 (8)	3 (6)	5 (10)
H	Severe	4	21 (42)	21 (42)	10 (20)	5 (10)	4 (8)	0 (0)
	Š	5	29 (58)	6 (12)	2 (4)	2 (4)	1 (2)	1 (2)
		6	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	2 (4)
		7	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

^{*}Data are presented as no. (%) unless indicated otherwise. Clinical Grade Score (CGS) was done on seven level ordinal scale as 1: indicated not hospitalized with resumption of normal daily activities; 2, Not hospitalized with limitations on normal daily activities; 3, Hospitalized and not receiving supplemental oxygen; 4, Hospitalized and receiving supplemental oxygen; 5, Hospitalized and receiving oxygen supplementation administered by a high-flow nasal cannula or noninvasive ventilation; 6, Hospitalized and receiving mechanical ventilation; and 7, Death.